The involvement of tyrosine phosphorylation signaling pathways in steroid-induced cell proliferation has received much attention. However, the adaptor molecule that mediates this interaction remains to be identified. In this communication, we identify p52 Shc as the mediator between tyrosine phosphorylation signaling and steroid signaling in steroid-responsive cell proliferation. Although the different LNCaP prostate cancer cells, C-33, C-51 and C-81, express similar levels of functional androgen receptor (AR), they exhibit different levels of androgen sensitivity. C-33 cell proliferation is highly responsive to the presence of androgens, whereas C-51 cell proliferation is comparatively less responsive to androgens. In contrast, C-81 cell proliferation is independent of androgens. In these cells, tyrosine phosphorylation levels of both p52 Shc and ErbB-2 were greatest in C-81 cells, comparatively less in C-51 cells and weaker in C-33 cells. The levels and activity of protein tyrosine phosphatase, cellular prostatic acid phosphatase, decreased correspondingly in those cells. In both androgen-independent, rapidly growing C-81 and ErbB-2 cDNA-transfected C-33 cells, p52
Shc was hyperphosphorylated at Tyr317 (Y317). Conversely, p52
Shc tyrophosphorylation was decreased in prostatic acid phosphatase cDNA-transfected stable subclones of C-81 cells, which restore androgen-sensitive proliferation and leads to slow growth rates. In C-33 cells, androgenstimulated cell proliferation correlated with tyrophosphorylation of ErbB-2 and increased phosphorylation of p52 Shc at Y317, but not at Y239, differing from phosphorylation patterns associated with epidermal growth factor (EGF) stimulation. Furthermore, overexpression of a mutant of p52 Shc , that is Y317F, blocks Y317 phosphorylation of endogenous p52
Shc and abolishes androgen-stimulated proliferation, but not EGF-stimulated proliferation. Thus, Y317 of p52
Shc serves as an important regulatory site that allows tyrosine phosphorylation pathways to moderate androgen sensitivity in human prostate cancer cells.
Introduction
Androgens are required for the development and maintenance of both male phenotype and male reproductive organs, including the prostate (Kokontis and Liao, 1999) . The normal prostate gland depends on testicular androgens and androgen receptor (AR) to maintain its functional integrity. Even in the early stage of prostate cancer, androgens are crucial for the growth of cancer cells. However, in advanced prostate cancer, androgen requirements are reduced or eliminated; that is, the androgen-independent phenotype (Sadar et al., 1999) . The loss of steroid hormone-dependent phenotype is also observed in advanced stages of breast cancer (Glauber and Kiang, 1992) , ovary cancer (Hua et al., 1995) and lymphoma (Weiss et al., 1990) . Although adaptation or epigenetic changes are proposed to be involved in the transition from the steroid hormonedependent to steroid hormone-independent phenotype (Culig et al., 1994; Koivisto et al., 1997; Karan et al., 2003) , the molecular mechanisms involved in the development of steroid hormone-independent phenomenon remain to be further delineated.
Protein tyrosine phosphorylation and dephosphorylation play a key role in regulating cellular proliferation and differentiation (Hunter, 1995; Weiss and Schlessinger, 1998) . When a protein tyrosine kinase (PTK) is abnormally activated or a protein tyrosine phosphatase (PTP) is inactivated, the aberrant tyrosine hyper-phosphorylation of cellular proteins may lead to malignant transformation of cells (Lin and Clinton, 1987; Hunter, 1995; Patarca, 1996) . The results of recent studies indicate crosstalks between tyrosine phosphorylation signaling and steroid action at the nongenomic level (Weigel, 1996; Lin et al., 1998; Weigel and Zhang, 1998; Feldman and Feldman, 2001; Grossmann et al., 2001) . Aberrant tyrosine phosphorylation may thus contribute to hormone-refractory growth of cancer cells. For example, in human breast cancer cells, overexpression of ErbB-2, at least in part due to gene amplification, leads to the loss of their steroid-hormone responsiveness (Houston et al., 1999) . In human prostate carcinomas, the ErbB-2 gene is not amplified, although the ErbB-2 protein level may be elevated in a small subgroup of advanced carcinomas (Strohmeyer and Slamon, 1994; Signoretti et al., 2000; Osman et al., 2001) . Interestingly, in androgen-independent human LNCaP C-81, PC-3 and DU 145 prostate cancer cells, ErbB-2 protein is tyrosine hyper-phosphorylated with an activated specific activity, while the ErbB-2 protein level is not elevated (Lin and Meng, 1996; Meng and Lin, 1998) . In C-81 cells, the highly tyrosine-phosphorylated ErbB-2 correlates with androgen-independent growth and PSA secretion Meng et al., 2000; Lee et al., 2003) . The molecular mechanism of this tyrosine phosphorylation signal pathway involving in androgen action requires further elucidation.
Prostatic acid phosphatase (PAcP) is a prostate epithelium-specific differentiation antigen and has both cellular and secretory forms (Lin et al., 1983; Lin and Clinton, 1987) . Classically, cellular prostatic acid phosphatase (cPAcP) is used as a biomarker of the tissue origin for metastasized prostate cancer cells, and secreted PAcP serves as a serological marker for the diagnosis of the cancer (Chu et al., 1982; Chu and Lin, 1998) . However, it should be noted that in prostate carcinomas, cPAcP expression is decreased, much lower than that in noncancerous prostate cells (Loor et al., 1981; Lin et al., 1983 Lin et al., , 2001 Solin et al., 1990) . Furthermore, point mutations are found in PAcP mRNA isolated from cancerous tissues, although the biological significance remains to be clarified (Vihko et al., 1988) . Several lines of evidence support the notion that cPAcP functions as a neutral PTPase in prostate epithelial cells Clinton, 1986, 1988; Vihko et al., 1993; Landry et al., 1996) and downregulates cell growth by dephosphorylating phosphotyrosine (p-Tyr) of ErbB-2 protein (Lin et al., 1994; Lin and Meng, 1996; Meng and Lin, 1998; Zhang et al., 2001) . It is further proposed that the interaction of cPAcP and ErbB-2 is involved in regulating androgen stimulation of human prostate cancer cell proliferation Meng et al., 2000) . This is because decreased cPAcP activity correlating with increased tyrosine phosphorylation of ErbB-2 concurs with androgen-independent growth of those AR-positive cells, as observed in advanced, hormone-refractory prostate carcinomas (Loor et al., 1981; Solin et al., 1990; Lin et al., 2001) . Conversely, expression of exogenous cPAcP restores their androgen responsiveness, and in those cells ErbB-2 tyrosine phosphorylation decreased Meng et al., 2000) . However, the adaptor protein that transduces androgen signaling by which cPAcP and ErbB-2 regulate androgen-responsive cell proliferation remains to be identified.
Shc (src homolog and collagen homolog) is an adaptor protein that can bind directly to activated receptor protein tyrosine kinases (RPTKs) (Ricci et al., 1995) , leading to an activation of the microtubuleassociated protein kinase or mitogen-activated protein kinase (MAPK) signal pathway . Shc protein has three isoforms, that is, p66 Shc , p52
Shc and p46 Shc , due to alternative splicing and the use of different start sites for translation (Migliaccio et al., 1997) . All three isoforms of Shc protein contain three functional regions: an SH2 carboxy-terminal region, an adjacent region rich in glycine and proline (CH1 region), which includes the Grb2 interaction site (tyrosine-317, Y317), and the phosphotyrosine-binding domain (PTB domain) Kavanaugh and Williams, 1994; van der Geer et al., 1995) . p66
Shc has a unique collagenhomologous region (CH2 region) in the amino-terminal portion (Migliaccio et al., 1997) . p52
Shc and p46 Shc are found in every cell type examined, while p66
Shc is predominantly expressed in epithelial cells Migliaccio et al., 1997) . Recent studies indicate that each isoform of Shc protein exhibits distinct biological activity. For example, it is shown that p52
Shc and p46
Shc , but not p66 Shc , link growth factor receptors to Ras by recruiting the adaptor Grb2 and guanine nucleotide exchange factor SOS, and subsequently activate the MAPK signal pathway Rozakis-Adcock et al., 1992; Migliaccio et al., 1997) . In several human breast cancer cell lines, the pTyr level of p52
Shc correlates with the activity of ErbB-2 (Stevenson and Frackelton, 1998) . Interestingly, in ERatransfected HeLa cells, p52
Shc is implicated in delivering the antiapoptotic activity of steroids by preventing those cells from etoposide-induced apoptosis (Kousteni et al., 2001) . Thus, p52
Shc may be involved in mediating cell survival signals by steroids.
The crosstalk between tyrosine phosphorylation and steroid hormone action is involved in regulating vital cellular functions. However, the adaptor protein mediating that crosstalk remains unknown. In this study, utilizing human prostate cancer cells as a model system, our data clearly showed that p52
Shc is responsible for transducing androgen stimulation of cell proliferation via the tyrosine phosphorylation signal pathway in human prostate cancer cells.
Results

Tyrosine phosphorylation of p52 Shc in different LNCaP cells
To identify the functional adaptor that mediates tyrosine phosphorylation signals for androgen-stimulated cell proliferation, we analysed the tyrosine phosphorylation status of Shc protein in LNCaP C-33, C-51 and C-81 cells. This is because these cells exhibit decreased androgen sensitivity in their growth regulation ( Figure 1a ) , while they express a similar level of functional AR (Figure 1b, top) . We also analysed the expression level of cPAcP and ErbB-2 because these two molecules are proposed to be involved in androgen action (Meng et al., 2000) . ErbB-2 and Shc were immunoprecipitated and their Shc with H-chain of anti-Shc immunoglobulin G (IgG), which has a nonspecific reaction with anti-pY Abs, it was difficult to detect the p-Tyr level of p46 Shc (Figure 1c ), as also shown in previous reports Gresham et al., 1998) . The membranes were stripped and reacted with anti-ErbB-2 and anti-Shc Abs, respectively. As shown in Figures 1b and c, Shc protein in C-33, C-51 and C-81 cells was 1.0, 2.4 and 3.1, respectively. Thus, in different LNCaP cells that express functional AR Igawa et al., 2002) , decreased androgen sensitivity correlates with decreased cPAcP level and increased p-Tyr levels of ErbB-2 and p52
Shc by over threefold.
To determine which tyrosine residue of p52 Shc is phosphorylated, we analysed the p-Tyr of Shc with two anti-phospho-Shc Abs, anti-pY317 p52
Shc and antipY239 p52
Shc . As shown in Figure 1d , the phosphorylation level of Y317, but not Y239, at p52
Shc was increased, higher in C-81 and C-51 cells than in C-33 cells, correlating with the observation by anti-pY Ab (Figure 1c ). Due to the sequence homology, these two Abs could also react with the phosphorylation of corresponding tyrosine residue at p46
Shc and p66 Shc (Upstate USA, Inc.). Nevertheless, as shown in Figure 1d , the strong signal of anti-pY317 Ab at p66 Shc position and that of anti-pY239 Ab at the p46 Shc position were apparently due to nonspecific signals that comigrated with Shc proteins. In summary, in different LNCaP cells, p52 Shc phosphorylation at Y317, but not Y239, correlates with activation of ErbB-2 as well as androgen-independent growth, while it inversely correlates with the expression of cPAcP.
The level of Grb2 protein, another adaptor in tyrosine phosphorylation signaling, was also analysed. There was a decrease of Grb2 protein level in LNCaP C-81 cells, compared to LNCaP C-33 cells (Figure 1e ). The results of semiquantitative analyses showed that the ratio of Grb2 protein to their corresponding b-actin level was 1.0, 0.95 and 0.81 in C-33, C-51 and C-81 cells, respectively. The result thus indicated that the Grb2 protein level does not directly correlate with ErbB-2 activation in human prostate cancer cells.
Androgen sensitivity and tyrosine phosphorylation of p52
Shc in PAcP cDNA-transfected stable subclones of LNCaP C-81 cells
To examine the role of p52
Shc in androgen-stimulated cell proliferation, we established two androgen-sensitive stable subclones, LNCaP-23 and LNCaP-40 cells, from LNCaP C-81 cells by transfection with a PAcP cDNA expression vector (a) Growth rates of different LNCaP cells. LNCaP cells were seeded at a density of 3 Â 10 4 cells/well in six-well culture plates in the regular culture medium. At 3 days after plating, the medium was replaced by a steroid-reduced medium containing 5% charcoal/dextran-treated FBS. After 48-h steroid starvation, one set of attached cells was counted as day 0. The remaining cells were refreshed with the steroid-reduced medium on days 0, 3 and 6, and the total cell numbers were counted on the indicated days. Bar, standard errors. (b) PAcP and b-actin protein levels in total cell lysates were detected with rabbit anti-PAcP serum and anti-b-actin Abs, respectively. ErbB-2 and Shc were immunoprecipitated following the procedure described in Materials and methods. Immunoblottings were performed with anti-p-Tyr Ab, followed by their specific Abs. treated with different concentrations of DHT. As shown in Figure 2c , after 3-day DHT-treatment, the growth of LNCaP-23 and LNCaP-40 cells was increased by over 50%, higher than the corresponding control C-81 cells, similar to LNCaP C-33 cells. In the same set of experiments, DHT stimulated parental C-81 cells by approximately 10%. Thus, the degree of androgenstimulated proliferation of these two transfectants was enhanced, higher than that of parental LNCaP C-81 cells, while it was similar to that of LNCaP C-33 cells. Furthermore, the expression of cPAcP correlated with decreased cell growth and restores androgen sensitivity of LNCaP C-81 cells.
We further analysed the activation status of ErbB-2 and p52 Shc in androgen-sensitive LNCaP-23 and LNCaP-40 stable subclones. As shown in Figure 2d , in LNCaP-23 and LNCaP-40 cells, the p-Tyr levels of ErbB-2 and p52
Shc decreased, lower than that in parental LNCaP C-81 cells, while they were similar to that in LNCaP C-33 cells expressing an endogenous PAcP (Figure 2a ). After stripping, the same membrane was incubated with anti-ErbB-2 and anti-Shc Abs, respectively. As shown in Figure 2d, 
Role of ErbB-2 in androgen-induced cell growth and Shc activation
To examine the role of ErbB-2 in the phenotype of androgen sensitivity and the growth of human prostate cancer cells, we analysed the effect of DHT on ErbB-2 cDNA-transfected LNCaP C-33 cells. Control cells were transfected with the vector alone. As shown in Figure 3a (left panel), the expression of exogenous ErbB-2 was evidenced by immunoblotting with an anti-Myc Ab. In those cells, ErbB-2 was greatly activated by its overexpression, indicated by tyrosine phosphorylation. In LNCaP C-81 cells were seeded at a density of 5 Â 10 4 cells/well in six-well plates in the regular medium for 3 days and then steroidstarved for 2 days as described in Figure 1 . One set of attached cells was harvested and counted as day 0. The remaining cells were refreshed with steroid-reduced medium on days 0, 3 and 6. Cells were harvested on days 3, 6 and 10 for counting. Similar results were obtained in two sets of independent experiments in duplicate wells. Bars, the range of duplicates. (c) Androgen effect on growth stimulation. Cells were plated as described above in regular medium for 3 days, and then steroid-starved in a steroid-reduced medium for 2 days. Cells were then fed with fresh steroid-reduced medium in the absence or presence of 1 or 10 nM DHT. At 3 days after treatment, cells were harvested and counted. The growth stimulation by DHT was normalized to the respective control cells (as 100%) that were cultured in the absence of androgen. The data shown are the mean of duplicate wells. Similar results were observed in three sets of independent experiments with duplicate wells. Bars, the range of duplicates. (d) p-Tyr levels of ErbB-2 and Shc proteins in LNCaP C-33, C-81 and PAcP cDNA-transfected C-81 cells . ErbB-2 and Shc protein were immunoprecipitated as described in Materials and methods and immunoblotted with anti-p-Tyr Ab, followed by anti-ErbB-2 and anti-Shc Abs, respectively. The results are representative of two sets of independent experiments the absence of DHT, the elevated expression of ErbB-2 enhanced the basal growth of ErbB-2 cDNA-transfected C-33 cells (Figure 3a, right panel) . Interestingly, the stimulating effect by DHT on the proliferation of those ErbB-2 cDNA-transfected LNCaP C-33 cells decreased, compared with the vector alone-transfected cells. Thus, the data clearly showed that increased ErbB-2 activity by activation (Figures 1 and 2 ) and/or overexpression (Figure 3 ) leads to increased basal cell proliferation and reduced androgen sensitivity of human prostate cancer cells.
To examine whether p52 Shc mediates ErbB-2 signaling in regulating the androgen sensitivity of prostate cells, we analysed the p-Tyr level of Shc in these ErbB-2 cDNA-transfected LNCaP C-33 cells. As shown in Figure 3b , the expression of exogenous ErbB-2 led to elevated tyrosine phosphorylation of p52 Shc . The overexpression of ErbB-2 in C-33 cells resulted in increased phosphorylation of Y317 at p52 Shc , but no apparent effect on Y239 of any Shc proteins (Figure 3b) . Thus, the data taken together (Figures 1 and 3 ) indicated that Y317 of p52
Shc plays a critical role in mediating ErbB-2 signaling in prostate cancer cells.
DHT effect on the tyrosine phosphorylation of Shc
Since pY317 of p52
Shc correlates with ErbB-2 activation as well as cell proliferation, we investigated androgen effect on Shc activation. As shown in Figure 4a 5 cells/well in six-well plates in a regular medium for 2 days and were transfected with the wild-type ErbB-2 cDNA (Erb). Control cells were transfected with the vector alone (Vec). The transfectants were cultured in the steroid-reduced medium containing 10% charcoal-treated FBS overnight. Next day, the medium was fed with a steroid-reduced medium for 24 h. Then, the medium was refreshed with this steroid-reduced medium. After 24 h, cells were cultured with steroid-reduced medium in the absence or presence of 10 nM DHT, and harvested and counted at the indicated days. The whole-cell lysates from day 0 were used for the immunoblot analyses with anti-Myc tag, anti-pY and antiErbB-2 Abs to detect the expression of exogenous ErbB-2 and the p-Tyr level of ErbB-2. (b) p-Tyr levels of Shc at Y317 and Y239 and Shc protein level in ErbB-2 cDNA-transfected C-33 cells. Another set of cells that were followed under the same culture condition as described for ErbB-2 cDNA transfection was harvested at 48 h after transfection. Control cells were transfected with the vector alone. Shc was immunoprecipitated and analysed with immunoblotting with anti-pY and anti-Shc Abs, respectively. The total cell lysates were used for the detection of the p-Tyr levels of Shc at Y317 and Y239 and the Shc protein level. Similar results were obtained from two sets of independent experiments
IP:
α-Shc was decreased in C-51 cells and further lower in C-81 cells (data not shown). Nevertheless, DHT had no detectable effect on the tyrosine phosphorylation of p66 Shc in those cells (Figure 4a ), even after a prolonged exposure (data not shown). DHT effect on the phosphorylation status of p52
Shc was further examined kinetically, compared with ErbB-2. The p-Tyr level of ErbB-2 was analysed by Western blot after immunoprecipitation, while the tyrosine phosphorylation level of Shc was reacted with anti-pY317-Shc and antipY239-Shc Abs, respectively. As shown in Figure 4b , 48 h after 10 nM DHT treatment, the pY317 level, but not pY239, of p52
Shc was greatly elevated, correlating with ErbB-2 activation. Apparently, a 48-h treatment with the physiological concentration of DHT (10 nM) could activate p52
Shc by phosphorylation at its Y317, but not Y239.
Effect of Y317F p52
Shc mutant on androgen-stimulated cell proliferation
To determine the role of p52
Shc in androgen action, we initially analysed whether mutation at Y317, that is, Y317F p52
Shc mutant, could have an effect on the p-Tyr level of endogenous p52
Shc since this mutant cannot be phosphorylated at Y317. As shown in Figure 5a , the expression of exogenous wild-type p52
Shc protein, that is, GST-p52 Shc , did not have an effect on the phosphorylation level of endogenous p52
Shc . However, the p-Tyr level of endogenous p52
Shc proteins in PC-3 cells was completely abolished by the expression of a high level of Y317F p52
Shc mutant, that is, GST-Y317F p52 Shc ( Figure 5a ). The dominant-negative effect of Y317F p52 Shc was also observed in LNCaP C-33 cells after a prolonged exposure, due to the low basal level of tyrophosphorylation (data not shown). The data thus indicated that Y317F p52
Shc mutant can function as a dominant-negative regulator to abolish the activation of endogenous p52
Shc in human prostate cancer cells.
To determine if Y317 of p52
Shc is mediating androgenstimulated proliferation of human prostate cancer cells, we analysed the effect of two dominant-negative mutants of p52
Shc that contain Y317F mutation, that is, the Y317F p52
Shc mutant as well as a triple mutant of p52 Shc consisting of Y239F, Y240F and Y317F, on androgen responsiveness of LNCaP C-33 cells. Control cells were transfected with the vector alone or with a cDNA encoding the wild-type p52 Shc . The results of preliminary studies showed that the triple mutant of p52 Shc exhibits an extremely toxic effect on cell growth, as observed in its transfected breast cancer cells (Stevenson et al., 1999) . In fact, it was very difficult to culture those triple mutant cDNA-transfected cells, much more difficult than Y317F p52 Shc -transfected cells (data not shown). Since it was impractical to analyse the effect of the p52 Shc triple mutant on androgen action of growth stimulation, we focused our efforts on analysing the effect by Y317F p52
Shc mutant. As shown in Figure 5b , in the steroid-reduced condition, Y317F p52
Shc mutant-transfected C-33 cells and both control cells grew slowly. In the presence of 10 nM DHT, after the initial rapid growth as observed at day 3, the proliferation of Y317F p52 Shc on the p-Tyr level of endogenous Shc. PC-3 prostate cancer cells were transiently transfected with the wild-type p52 Shc (Wt) or the pEBG-Shc-Y317F (317F) mutant cDNA. As a control, cells were transfected with the vector alone (Vec). At 2 days after transfection, cell lysates were prepared, and the immunoprecipitation and immunoblotting were performed. (b) Effect of the wild type and Y317F mutant of p52
Shc on the androgen-stimulated proliferation of LNCaP C-33 cells. Cells were transiently transfected with a pEBG vector (Vec), pEBG-Shc (WT), or pEBG-Shc-Y317F (Y317F), cultured in the presence or absence of 10 nM DHT, and were harvested for cell counting at different time intervals as indicated in the figure. The expression of exogenous p52
Shc was detected by immunoblot analyses and presented in the bottom of the figure. A total of six sets in duplicates of independent experiments with similar results were obtained by two individuals (three sets by each individual). * and dots indicate nonspecific bands or degraded proteins of exogenous p52
Shc . Bars denote the range of duplicates were performed to confirm the expression of exogenous p52 Shc protein (Figure 5b , bottom panel). Thus, in Y317F p52
Shc mutant-transfected LNCaP C-33 cells, androgen-promoted cell proliferation is abolished after initial growth stimulation. p52
Shc is apparently responsible for transducing signals of androgen-stimulated proliferation in androgen-sensitive prostate cancer cells.
Effect of Y317F p52
Shc mutant on EGF-stimulated cell growth
To further clarify the specificity of p52
Shc in androgen action, the profile of Shc activation upon epidermal growth factor (EGF) treatment was examined in androgen-sensitive LNCaP C-33 cells. As shown in Figure 6a , Western blot analyses showed that in EGFtreated cells, tyrosine phosphorylation of all three members of Shc family was greatly increased. We subsequently analysed the specific tyrosine residue(s) of Shc that is phosphorylated upon EGF treatment. EGF greatly stimulated tyrosine phosphorylation of all three members of Shc protein at both Y317 and Y239, although to a lesser degree at Y239 of p66
Shc (Figure 6a , bottom panels). Subsequently, the effect of Y317F p52
Shc mutant on EGF signaling in LNCaP C-33 cells was analysed. As shown in Figure 6b , the expression of Y317F p52
Shc mutant, as the exogenous wild-type p52
Shc , had no effect on EGF-stimulated proliferation of LNCaP C-33 cells. Thus, it is conceivable that since EGF can effectively activate all three members of Shc family at both tyrosine residues in prostate cancer cells, differing from androgen signaling (Figure 4 ), Y317 p52
Shc mutant alone may not be sufficient to reduce EGF stimulation of LNCaP C-33 cells.
Discussion
Members of the Shc family are involved in signaling events that lead to mitogenesis and differentiation in several tyrosine kinase-involved pathways. In this communication, our data clearly show that p52
Shc is also the primary adaptor protein for mediating the mitogenic signal of androgens in human prostate cancer cells. Moreover, the Y317 residue of p52
Shc serves as the active site modulating androgen-stimulated cell proliferation in those cells.
Shc proteins can be phosphorylated at Y239 and Y317 by a variety of PTKs (Luzi et al., 2000; Ravichandran, 2001) . Interestingly, physiological concentrations of androgens upregulate the phosphorylation of p52
Shc exclusively at Y317 in androgen-sensitive prostate cancer cells (Figure 4) . Similarly, ErbB-2 cDNA transfection of C-33 cells results in an increased Y317 phosphorylation of p52 Shc , but no apparent effect on other Shc members or Y239 phosphorylation (Figure 3) . One possible mechanism explaining androgen-stimulated phosphorylation of p52 Shc is that androgen administration leads to the activation of ErbB-2 (Meng et al., 2000) , which subsequently phosphorylates the Y317 of p52
Shc (Figure 4b ). This is consistent with Effect of overexpressed wild type and Y317F mutant of p52 Shc on EGF-stimulated cell growth. (a) Subconfluent C-33 cells were maintained in a steroid-reduced medium for 24 h before being exposed to 0 and 10 ng/ml EGF, respectively, for 16 h. Cells were then harvested and lysed for immunoprecipitation. Shc was immunoprecipitated and immunoblotted with anti-p-Tyr Ab, followed by an anti-Shc Ab after stripping. The total cell lysates were used for the detection of the p-Tyr levels of Shc at Y317 and Y239 and the Shc protein levels. Similar results were obtained from two sets of independent experiments. (b) C-33 cells were transiently transfected with pEBG vector (Vec), pEBG-Shc (WT), or pEBGShc-Y317F (Y317F). At 6 h after transfection, cells were cultured in a phenol red-free RPMI 1640 medium supplemented with 10% charcoal-treated FBS overnight and subsequently maintained in the steroid-reduced medium for an additional day. Then, cells were fed with the fresh steroid-reduced medium with or without 10 ng/ml EGF. Cells were harvested and counted at different time intervals as indicated in the figure. The expression of exogenous p52
Shc was detected with immunoblot analysis and presented in the bottom of figure. Three sets in duplicates of independent experiments with similar results were performed by two individuals. It should be noted that the overall low expression levels of Shc proteins in EGFtreated, wild-type p52
Shc -transfected cells were due to the loading errors. Bars denote the range of duplicates the observations that Shc proteins mediate signals from NDF-activated ErbB-2 in human prostate cancer cells (Grasso et al., 1997) . Alternatively, DHT-AR complexes activate c-Src activity by which p52 Shc is phosphorylated (Lennartsson et al., 1999; Migliaccio et al., 2000) . However, this may not be the case since the activation of c-Src by DHT-AR complexes after 10 nM DHT treatment is a rapid and transient event within 6 h (Migliaccio et al., 2000 ; MS Lee, TC Yuan and MF Lin, unpublished observations), while 10 nM DHT effect on Y317 phosphorylation of p52
Shc is observed at 48 h after treatment (Figure 4b ). It is thus evidenced that in DHTtreated C-33 cells, activated ErbB-2 phosphorylates Y317 of p52 Shc .
The Y317F p52
Shc mutant cannot be phosphorylated at Y317, while it can compete with endogenous p52 Shc for interacting with ErbB-2 protein and thus behaves as a dominant-negative mutant (Ravichandran et al., 1995; Stevenson et al., 1999) . Nevertheless, little is known as to why Y317F p52
Shc mutant has no inhibitory effect on the initial androgen-stimulated proliferation of C-33 cells (Figure 5b ). The inhibitory effect by Y317F p52 Shc mutant appears to occur after approximately half of one cell cycle upon androgen treatment. Apparently, Y317F p52
Shc cannot block those cells that have already entered their cell cycle. The same parallel can be drawn between our observation of delayed growth arrestment by Y317F p52
Shc in androgen regulation and the observation that growth arrest by steroid starvation occurs only after the completion of the cell cycle (Gao et al., 1999; MF Lin and MS Lee, unpublished observations) . Similarly, in ErbB-2-positive breast cancer cells, the Y317F p52 Shc mutant blocks the cell cycle progression only at the G0-G1 and the G2-M junctions (Stevenson et al., 1999) . Alternatively, p52
Shc mediating androgen-stimulated cell proliferation is a secondary response, that is, it transduces the growth-stimulation signal that is derived from the androgen-induced autocrine system, including the genomic events. In this mode of regulation, p52 Shc does not participate in the initial stage of DHT stimulation. This can also explain why androgenactivated p52
Shc tyrosine phosphorylation is observed at the 48-h treatment (Figure 4b) . Certainly, the details of the molecular mechanism for the role of p52 Shc in androgen action require further investigations.
Our data further point out that Shc family members are differentially responsible for transducing different signals in cell growth regulation. For instance, EGF greatly activates all three members of Shc family by phosphorylation at both Y239 and Y317 residues (Figure 6a ), while DHT only activates p52
Shc by phosphorylation at Y317 (Figure 4b ). Therefore, Y317F p52
Shc mutant could block androgen-stimulation signals (Figure 5b ). We further propose that Grb2 serves as an additional adaptor for transducing growth factor signals, but is not involving in steroid signaling. The requirement of multiadaptors for EGF signaling versus the sole requirement of p52
Shc by DHT can be explained in part by the natures of growth factors and steroid hormones, that is, growth factors exhibit a burst, transient effect, while steroids in general have a mild, prolonged action. Interestingly, both EGF and DHT have the same effects on downregulating cPAcP activity, activating ErbB-2 protein and stimulating growth of androgen-sensitive prostate cancer cells (Lin et al., 1992 Meng and Lin, 1998; Meng et al., 2000) . Thus, diverse signals activate different adaptor proteins for their cell growth regulation. Further experiments are required to determine the role of each adaptor protein in corresponding specific signal pathway.
As a proposed model shown in Figure 7a , the results taken together indicate that in AR-positive, cPAcPexpressing human prostate cancer cells, for example, C-33, LN-23 and LN-40 cells, cPAcP dephosphorylates ErbB-2 and thus inhibits the signal pathway from ErbB-2 via p52
Shc to MAPK, resulting in downregulation of the growth of these cells. In these cells in the presence of androgens (Figure 7b) , AR is activated, and cPAcP activity is decreased (Lin et al., 1992; Meng et al., 2000) , Shc to MAPK and a decrease of cell proliferation. (b) Androgens upregulate the growth of androgensensitive prostate cells. Two pathways may be involved in this action: 1 Androgens can suppress the expression of cPAcP, and/or 2 androgens activate a PTK activity in those cells, resulting in the hyperactivation of ErbB-2. This androgen-activated ErbB-2 will phosphorylate Y317 of p52
Shc , leading to the activation of MAPKs and the promotion of cell growth resulting in an elevated tyrophosphorylation of ErbB-2 and p52
Shc . Subsequently, ERK/MAPKs are activated, leading to stimulated cell proliferation. In AR-positive C-81 cells, ErbB-2 is activated, in part due to the lack of cPAcP expression, leading to the activation of p52
Shc as well as ERKs and androgen-independent cell proliferation. In those cells, AR is also activated, as indicated by androgen-independent PSA secretion . Conversely, in PAcP cDNA-transfected C-81 cells, including LN-23 and LN-40 cells, ectopically expressed cPAcP dephosphorylates ErbB-2, resulting in a decreased cell proliferation and these cells restore androgen sensitivity. This model therefore provides an explanation for hormone-refractory prostate tumor progression as observed in clinical archival specimens, in which functional AR is present (van der Kwast et al., 1991; Grossmann et al., 2001) , cPAcP is decreased (Loor et al., 1981; Solin et al., 1990; Lin et al., 2001) , and the ERK/MAPKs are highly activated by phosphorylation (Gioeli et al., 1999; Price et al., 1999) , despite the fact that the ErbB-2 gene is not amplified in these carcinomas (Strohmeyer and Slamon, 1994; Signoretti et al., 2000) . In these tumor cells, AR is activated as indicated by the rebound of androgen-independent PSA secretion (Chu and Lin, 1998) . The functional molecules in this pathway could thus serve as additional targets for developing novel pharmacotherapeutical agents toward this cancer. These can be accomplished by, for example, restoring the expression of cPAcP and developing specific Abs and inhibitors to the activated target proteins. Interestingly, inhibition of the ErbB-2-p52 p52 Shc signal pathway by specific inhibitors to ERKs plus chemotherapeutic agents can reduce both the drug dosage and its toxicity and enhance the efficacy on growth suppression (Zelivianski et al., 2003) . In conclusion, our data reveal that adaptor proteins are differentially responsible for transducing different external stimuli, and that p52
Shc is a functional adaptor that mediates androgen signals for the growth stimulation of human prostate cancer cells.
Materials and methods
Materials
Fetal bovine serum (FBS), RPMI 1640 culture medium, gentamicin, EGF, horseradish peroxidase-conjugated antimouse IgG and LipofectAMINE PLUSt reagents were purchased from Invitrogen (Carlsbad, CA, USA). Charcoal/ dextran-treated, certified FBS (lot AGD6463, testosterone o3.0 ng/dl) was obtained from Hyclone (Logan, UT, USA). Protein molecular weight standard markers, acrylamide, and the Bio-Rad Protein Assay kit were obtained from Bio-Rad (Hercules, CA, USA). Polyclonal anti-Shc Ab for immunoprecipitation, monoclonal anti-p-Tyr Ab (4G10), polyclonal anti-phospho-Shc-Y317 Ab, and polyclonal anti-phospho-Shc-Y239 Ab for immunoblotting were from Upstate USA, Inc. (Charlottesville, VA, USA). Monoclonal anti-Shc Ab (PG797), polyclonal anti-Grb2 Ab, and polyclonal antiErbB-2 Abs (C-18 and K-15) for immunoblotting, monoclonal anti-ErbB-2 Ab (9G6) for immunoprecipitation and horseradish peroxidase-conjugated anti-rabbit IgG were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Normal mouse IgG was a gift from Dr Richard G MacDonald, UNMC. Rabbit anti-PAcP antiserum was obtained as described previously (Lin et al., 1993 ). An enhanced chemiluminescence (ECL) detection system was purchased from Pierce (Rockford, IL, USA). DHT was obtained from Sigma (St Louis, MO, USA). The p52 Shc plasmids, including the wild type, the Y317F mutant, the Y239F/Y240F double mutant and the Y239F, Y240F and Y317F triple mutant, were gifts from Dr KS Ravichandran at the Beirne Carter Center for Immunology Research and Department of Microbiology (University of Virginia, Charlottesville, VA, USA).
Cell culture
Human prostate carcinoma cell lines LNCaP (Horoszewicz et al., 1983) and PC-3 (Kaighn et al., 1979) were originally purchased from the American Type Culture Collection (Rockville, MD, USA) and routinely maintained in the regular culture medium, that is, phenol red-positive RPMI 1640 medium supplemented with 5% FBS, 1% glutamine and 0.5% gentamicin. Cells were split once per week, which was defined as one passage. LNCaP cells with passage numbers less than 33 were designed as C-33, those with numbers greater than 80 as C-81, and those with numbers between 35 and 80 as C-51 Igawa et al., 2002) . In general, LNCaP cells with passage numbers between 45 and 60 were used as C-51 cells for experiments. Following the passage of LNCaP cells in regular maintenance, the androgen sensitivity of cell growth stimulation is decreased, despite the expression of functional AR Igawa et al., 2002) . Thus, LNCaP C-33 cells are androgen-sensitive, while LNCaP C-81 cells exhibit androgenindependent growth Igawa et al., 2002) . PC-3 cells are androgen-insensitive cells (Kaighn et al., 1979) . For DHT treatments, a steroid-reduced medium, that is, phenol red-free RPMI 1640 medium containing 5% charcoal/dextrantreated, heat-inactivated certified FBS, was used .
PAcP cDNA stable transfectants
LNCaP-23 and -40 were stable subclones of LNCaP C-81 cells transfected with the wild-type human PAcP cDNA driven by a pCMV-neo expression vector, as described previously .
Transient transfection of Shc and ErbB-2 cDNAs
Cells were seeded in the regular culture medium for 48 h with a density of 2 Â 10 5 cells/well in six-well plates for cell growth analysis or 1 Â 10 6 cells/dish in 100 mm Petri dishes for immunoprecipitation. Transient transfections were carried out utilizing 4 ml Lipofectamine Plus reagents to introduce 1 mg plasmid DNA into LNCaP C-33 cells/well in six-well plates in a serum-free medium. Plasmid DNAs included pEBG vector, pEBG wild-type p52 Shc , pEBG-p52 Shc -Y317F, pEBGp52 Shc -Y239F and Y240F and pEBG-p52 Shc -Y239F, Y240F and Y317F mutants (Ravichandran et al., 1995; Walk et al., 1998) , as well as a pcDNA3.1A vector and the pcDNA3.1A-HER2-Myc plasmid (Meng et al., 2000) . Transient transfection for the ectopic expression of p52
Shc cDNA variants in PC-3 cells was performed in 100 mm Petri dishes by mixing 4 mg p52 Shc cDNA variants with 30 ml Lipofectamine Plus reagent. After the incubation of cells with the transfection solution for 6 h, cells were maintained in a medium as described for each specific experiment.
Cell growth curve
To analyse the effect of Shc on androgen-or EGF-stimulated cell growth after transfection, the Shc cDNA-transfected LNCaP cells were maintained in the phenol red-free RPMI 1640 medium containing 10% charcoal/dextran-stripped FBS, 1% glutamine and 0.5% gentamicin. After 24 h, cells were fed with a steroid-reduced medium containing 5% charcoal/ dextran-stripped FBS. At 2 days after androgen starvation, one set of attached cells was harvested and counted as day 0, and the remaining cells were fed with fresh steroid-reduced medium in the presence or absence of 10 nM DHT or 10 ng/ml EGF. The cells were harvested and counted by a Coulter counter on days 3 and 6, while the remaining cells at day 3 were fed with the corresponding fresh medium.
Immunoprecipitation and immunoblotting
Subconfluent cells were harvested by scraping. The pelleted cells were rinsed with ice-cold 20 mM HEPES-buffered saline, pH 7.0, and then lysed in ice-cold cell lysis buffer containing protease and phosphatase inhibitors, that is, 20 mM HEPES, pH 7.0, containing 0.5% deoxycholic acid, 0.15 M NaCl, 0.1% SDS, 1% Nonidet P-40, 4 mM EDTA, 10 mM NaF, 0.1 mM ZnCl 2 , 10 mM Na 4 P 2 O 7 , 2 mM sodium orthovanadate, 2 mM phenylmethylsulfonyl flouride, 1 trypsin-inhibitory unit of aprotinin, 4 mM leupeptin and 1 mM pepstatin A. The lysates were spun at 1600 Â g for 10 min at 41C. The protein concentration of the supernatant was determined by using a Bio-Rad Protein Assay kit. For immunoprecipitation, an aliquot of 2 mg lysate proteins was incubated with 4 mg antiShc Ab-conjugated protein A-Sepharose complex at 41C. The immunoprecipitation of ErbB-2 was performed as described previously . The immunocomplexes were spun at 700 Â g for 5 min, washed four times with ice-cold lysis buffer and resuspended in an SDS-PAGE sample buffer.
For immunoblotting, an aliquot of the total lysate protein (30 mg) or the supernatant of immunoprecipitated complexes in SDS-PAGE sample buffer was electrophoresed and transferred onto a nitrocellulose filter (Micron Separation Inc., MA, USA). Filters were incubated with corresponding Abs, and the proteins were visualized by an ECL detection system . For rehybridization, the filters were stripped with a stripping buffer (62.5 mM Tris-HCl, pH 6.8, containing 100 mM b-mercaptoethanol and 2% SDS) at 501C for 30 min. After two washes with TBST buffer (20 mM Tris-buffered saline, pH 7.5, containing 0.1% Tween 20), the filters were reacted with specific Abs, and the signal was detected by the ECL method.
Semiquantification
The relative tyrosine phosphorylation levels of p52
Shc and ErbB-2 were semiquantified by densitometric analyses of autoradiograms with different exposure time periods using Molecular Dynamics equipment and its software program. The p-Tyr level was then normalized to the corresponding protein level.
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